Department of Nephrology and Transplantology, Medical University in Bialystok, Bialystok, Poland.
Angiology. 2013 Apr;64(3):181-7. doi: 10.1177/0003319712459212. Epub 2012 Sep 11.
Hypertension and cardiovascular complications are very common in chronic kidney disease (CKD). Overactivation of sympathetic nervous system is also widely recognized in CKD. Renalase may play an important role in the control of blood pressure (BP) by its regulatory function of catecholamine metabolism. Renalase could be synthesized not only by the kidney but also by cardiomyocytes, liver, and adipose tissue. It probably exerts a hypotensive action, at least in animal models. Whether it metabolizes catecholamines remains to be proved. Another issue that remains to be resolved is the relationship between renalase and renal natriuresis and phosphaturia. In this review, the updated experimental and clinical data on renalase are presented and possible interactions with the endothelium are discussed. Renalase is "a new postulated therapeutic target." Proof of concept studies are needed to define the pathophysiological link between the kidney, sympathetic tone, BP, and cardiovascular complications.
高血压和心血管并发症在慢性肾脏病(CKD)中非常常见。交感神经系统的过度激活在 CKD 中也得到了广泛的认可。肾酶可能通过调节儿茶酚胺代谢来发挥控制血压(BP)的重要作用。肾酶不仅可以由肾脏合成,还可以由心肌细胞、肝脏和脂肪组织合成。它可能至少在动物模型中发挥降压作用。它是否代谢儿茶酚胺仍有待证实。另一个需要解决的问题是肾酶与肾排钠和排磷之间的关系。在这篇综述中,介绍了肾酶的最新实验和临床数据,并讨论了与内皮细胞的可能相互作用。肾酶是“一个新的假定治疗靶点”。需要进行概念验证研究来确定肾脏、交感神经张力、BP 和心血管并发症之间的病理生理联系。